论文部分内容阅读
作者为151例血液恶性肿瘤患者在大剂量化疗和单次大剂量照射后做了同种基因骨髓移植术。化疗分为:经典化疗:有复发“普通风险”(处于缓解期)的126个病人,单用环磷酰胺(60mg/kg,于移植术前第4天和第5天用);强化化疗:有复发“高风险”(处于恶化期)的另外25个病人除用环磷酰胺外,还联合了其它化疗药,其中,22人联用了CCNU(100～300mg/m~2),9人联用了VP_(16)(200～500mg/m~2)或阿糖胞苷(200mg/m~2),2人联用了羟基服(4g/m~2)或正定霉素(120mg/m~2)。所有患者都用Co~(60)在骨髓移植的前一天行
The authors of the 151 patients with hematological malignancies underwent high-dose chemotherapy and single-dose high-dose irradiation to perform allogeneic bone marrow transplantation. Chemotherapy was divided into: classical chemotherapy: 126 patients with recurrent “ordinary risk” (in remission), cyclophosphamide alone (60 mg/kg, on the 4th and 5th days before transplantation); intensive chemotherapy: In addition to cyclophosphamide, 25 patients who had a “high risk” of recurrence (in an exacerbation phase) were also combined with other chemotherapeutic agents. Among them, 22 were combined with CCNU (100 to 300 mg/m~2) and 9 were VP_(16) (200–500 mg/m~2) or cytarabine (200 mg/m~2) was used in combination with 2 hydroxypropyl (4 g/m~2) or undomycin (120 mg/ m~2). All patients were treated with Co~(60) on the day before bone marrow transplantation.